Sedana Medical has been approved for trading on Nasdaq Stockholm

Nasdaq Stockholm's Listing Committee has today informed that Sedana Medical AB's (publ) (the "Company" or "Sedana Medical") application for admission to trading of the Company's shares on Nasdaq Stockholm has been approved. The approval is subject to customary conditions being met, including that a prospectus is approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”). The first day of trading on Nasdaq Stockholm is scheduled for 25 January 2023 and the last day of trading on Nasdaq First North Growth Market is scheduled for 24 January 2023.

“Over the last years, Sedana Medical has grown into a global company, improving lives of mechanically ventilated intensive care patients in more than 40 countries. Now we are taking another important step in our growth journey as we transition from Nasdaq First North Growth Market to Nasdaq Stockholm, the Main Market. My gratitude goes to my team and our advisors who have contributed to achieving this important milestone”, says Johannes Doll, President and CEO, Sedana Medical.

Sedana Medical has been listed on Nasdaq First North Growth Market since 21 June 2017 and the Board of Directors assesses that a move to Nasdaq Stockholm would provide a stamp of quality and reflect the maturity of the Company. In addition, being traded on a regulated market is expected to give the Company further access to the Swedish and international capital markets, increase the liquidity of the Company’s shares and improve the conditions for broadening the Company’s shareholder base, which in turn is assessed to promote the Company’s continued growth and be value creating in the long term for the Company’s shareholders. In light of the above, the Board of Directors of Sedana Medical has applied for admission to trading of the Company's shares on Nasdaq Stockholm. Today, Nasdaq Stockholm's Listing Committee has informed that Sedana Medical meets the requirements for admission of the Company's shares to trading on Nasdaq Stockholm, subject to customary conditions, including approval of a prospectus by the SFSA.

The Company’s shares will be traded under the current ticker (SEDANA) and ISIN code (SE0015988373). There is no capital raising or new share issue in connection with the listing change, and shareholders in Sedana Medical do not need to take any actions.

Prospectus

For further information, please refer to the prospectus that has been prepared in connection with the listing, which is expected to be approved and registered by the SFSA and published on the Company's website before the first day of trading on Nasdaq Stockholm's main market.

Advisers

Pareto Securities AB and Advokatfirman Lindahl KB are Sedana Medical’s financial and legal advisers respectively, in connection with the listing change.

 

For additional information, please contact:
Johannes Doll, CEO, +46 76 303 66 66
Johan Spetz, CFO, +46 730 36 37 89
ir@sedanamedical.com

 

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

 

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.